Overall, there is a sizeable subset of HNSCC patients with receptor-tyrosine kinase (RTK) mutations (e.g., NTRK1/2/3, ERBB1/2/3/4, PDGFRs, MET, etc.)and it remains to be carefully defined if these RTK mutations will cause any drug sensitivity in preclinical models or in patients. Here, NTRK1 is linked to head and neck squamous cell carcinoma.